Evidence map›Paper›PMID 41031875›Full record

ArticleBriefings in bioinformatics2025

SurvBoard: standardized benchmarking for multi-omics cancer survival models.

David Wissel, Nikita Janakarajan, Aayush Grover, Enrico Toniato, Maria Rodríguez Martínez, Valentina Boeva

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. A pan-cancer multi-omicFrontiers in artificial intelligence · 2026
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David WisselDepartment of Computer Science, ETH Zurich, Zurich, Switzerland.
Nikita JanakarajanDepartment of Computer Science, ETH Zurich, Zurich, Switzerland.
Aayush GroverDepartment of Computer Science, ETH Zurich, Zurich, Switzerland.
Enrico ToniatoIBM Research Europe, Zurich, Switzerland.
Maria Rodríguez MartínezIBM Research Europe, Zurich, Switzerland.
Valentina BoevaDepartment of Computer Science, ETH Zurich, Zurich, Switzerland.

Funding

European Union's Horizon 2020 826121SDSCSwiss Government Excellence Scholarship 2021.0468Swiss National Science Foundation CRSII5 193832
6 · The paper itself

Abstract

Multi-omics data, which include genomic, transcriptomic, epigenetic, and proteomic data, are gaining increasing importance for determining the clinical outcomes of cancer patients. Several recent studies have evaluated various multimodal integration strategies for cancer survival prediction, highlighting the need for standardizing model performance results. Addressing this issue, we introduce SurvBoard, a benchmark framework that standardizes key experimental design choices. SurvBoard enables comparisons between single-cancer and pan-cancer data models and assesses the benefits of using patient data with missing modalities. We also address common pitfalls in preprocessing and validating multi-omics cancer survival models. We apply SurvBoard to several exemplary use cases, further confirming that statistical models tend to outperform deep learning methods, especially for metrics measuring survival function calibration. Moreover, most models exhibit better performance when trained in a pan-cancer context and can benefit from leveraging samples for which data of some omics modalities are missing. We provide a web service for model evaluation and to make our benchmark results easily accessible and viewable: https://www.survboard.science/. All code is available on GitHub: https://github.com/BoevaLab/survboard/. All benchmark outputs are available on Zenodo: 10.5281/zenodo.11066226. A video tutorial on how to use the Survboard leaderboard is available on YouTube at https://youtu.be/HJrdpJP8Vvk.

Indexed as

BenchmarkingComputational BiologyGenomicsNeoplasmsSoftwareHumansMultiomicsProteomicsSurvival Analysiscancerdeep learningmulti-omicssurvival analysis

Identifiers

PMID41031875
PMCPMC12486238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.